Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Rutgers, The State University of New Jersey: Clinical Trials & FDA Approval Profile

Rutgers, The State University of New Jersey (Global / Institutional) sponsors 54 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 33 active protocols (25 recruiting now), 12 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)16.7%
Median Closed Enrollment vs National (145 pts)28 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Rutgers, The State University of New Jersey
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)54
Active Pipeline (Recruiting Now)33 (25)
Completed vs Stopped Early12 / 9 (16.7%)
Median Closed Actual Enrollment28 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Rutgers, The State University of New Jersey
Hospital Research SiteLocationShared Protocols
Rutgers Cancer Institute of New JerseyNew Brunswick, NJ15

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Rutgers, The State University of New Jersey
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05806931Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal CancerPhase IIRECRUITING
NCT05559164Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 TargetedPhase IIRECRUITING
NCT05358548ATATcH Alternating Treatment Plans for Advanced CancerPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Rutgers, The State University of New Jersey Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI